相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology
Nicolas Pierre et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2021)
Short Disease Duration Is Associated With Increased Risk of Treatment Failure in Biologic-Treated Patients With Ulcerative Colitis
Nghia H. Nguyen et al.
INFLAMMATORY BOWEL DISEASES (2020)
Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies
Remo Panaccione et al.
JOURNAL OF CROHNS & COLITIS (2019)
Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials
Shomron Ben-Horin et al.
BMJ OPEN (2019)
Shorter Disease Duration Is Associated With Higher Rates o f Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis
David M. Faleck et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Molecular classification of Crohn's disease reveals two clinically relevant subtypes
Matthew Weiser et al.
GUT (2018)
Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study
Isabelle Cleynen et al.
LANCET (2016)
Disease Duration Did Not Influence the Rates of Loss of Efficacy of the Anti-TNF Therapy in Latin American Crohn's Disease Patients
Paulo Gustavo Kotze et al.
DIGESTION (2015)
Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis
Sanjay K. Murthy et al.
INFLAMMATORY BOWEL DISEASES (2015)
Factors Associated with Durable Response to Infliximab in Crohn's Disease 5 Years and Beyond: A Multicenter International Cohort
Pascal Juillerat et al.
INFLAMMATORY BOWEL DISEASES (2015)
Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial
Reena Khanna et al.
LANCET (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
David Moher et al.
SYSTEMATIC REVIEWS (2015)
Increased Effectiveness of Early Therapy With Anti-Tumor Necrosis Factor-α vs an Immunomodulator in Children With Crohn's Disease
Thomas D. Walters et al.
GASTROENTEROLOGY (2014)
Adalimumab for Crohn's disease: Long-term sustained benefit in a population-based cohort of 438 patients
Charlotte P. Peters et al.
JOURNAL OF CROHNS & COLITIS (2014)
American Gastroenterological Association Institute Technical Review on the Use of Thiopurines, Methotrexate, and Anti-TNF-α Biologic Drugs for the Induction and Maintenance of Remission in Inflammatory Crohn's Disease
Themistocles Dassopoulos et al.
GASTROENTEROLOGY (2013)
Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease
S. Schreiber et al.
JOURNAL OF CROHNS & COLITIS (2013)
C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I
W. Reinisch et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process
Laurent Peyrin-Biroulet et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
Axel Dignass et al.
JOURNAL OF CROHNS & COLITIS (2012)
Development of the Crohn's Disease Digestive Damage Score, the Lemann Score
Benjamin Pariente et al.
INFLAMMATORY BOWEL DISEASES (2011)
A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization
Abderrahim Oussalah et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data
Stefan Schreiber et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2010)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
A. Dignass et al.
JOURNAL OF CROHNS & COLITIS (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease:: an open randomised trial
Geert D'Haens et al.
LANCET (2008)
Treating Individuals 4 - Can meta-analysis help target interventions at individuals most likely to benefit?
SG Thompson et al.
LANCET (2005)
分享论文
